Iodopyrazine → 6-Methyl-4-pyrazin-2-yl-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide
반응식
[CH3:1][C:2]1[N:3]=[C:4]([NH:7][C:8]([C:10]2[CH:15]=[C:14](B3OC(C)(C)C(C)(C)O3)[CH:13]=[C:12]([CH3:25])[N:11]=2)=[O:9])[S:5][CH:6]=1.I[C:27]1[CH:32]=[N:31][CH:30]=[CH:29][N:28]=1>>[CH3:1][C:2]1[N:3]=[C:4]([NH:7][C:8]([C:10]2[CH:15]=[C:14]([C:27]3[CH:32]=[N:31][CH:30]=[CH:29][N:28]=3)[CH:13]=[C:12]([CH3:25])[N:11]=2)=[O:9])[S:5][CH:6]=1참가 물질
3
실험 절차
The title compound, was prepared from 6-Methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide in accordance with the general method of example 131, step 2 using 2-iodopyrazine instead of 3-Trifluoromethyl-5-bromopyridine to yield the final compound as a white solid, MS (ISP): m/e=312.1 (M+H)+.
출처 및 근거
- ORD 기록
- ord-8c4cbd5301b4455f8372cd737bc5f8d8
- 출처 데이터셋
- uspto-grants-2011_05
- 특허 번호
- US07951824B2
반응 노트
불러오는 중…